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Protection of neutropenic mice from lethal 
Candida albicans infection by recombinant 
interleukin 1*
Natural and synthetic immunomodulators that increase nonspecific resistance to 
infection are also known to induce interleukin 1 (IL1) production. Previous studies 
have demonstrated a protective effect of recombinant human IL 1(3 against death 
from infection caused by Pseudomonas aeruginosa. In the present study we investi­
gated the effect of IL 1(3 or IL la  on the survival of neutropenic mice with a lethal 
Candida albicans infection. Mice with cyclophosphamide-induced neutropenia were 
injected with 3 x 10D C. albicans i.v. When 80 ng IL1(3 was given as a single i.p. 
injection 24 h before the infection, survival compared to that in control animals was 
as follows: 100% vs. 97% at 24 h, 83% vs. 70% at 48 h and 70% vs. 23% at 72 h after 
the infection (p<0.01). The effect of IL1 was also apparent when it was given Zi h 
before or 6 h after the infection. The results obtained with 80 ng IL la  given at 24 h 
before infection were similar to that obtained with IL1(3. The numbers of Candida 
cultured from the blood, liver, spleen, and kidney were not significantly different in 
ILip-treated and control animals. Passive transfer of serum obtained from mice 
pretreated with IL 1 to recipient mice did not provide protection against a subsequent 
lethal candidal infection. In conclusion, the present study demonstrates that IL ip and 
IL la  prolong survival in neutropenic mice with a lethal C. albicans infection.
1 Introduction
Disseminated infection caused by Candida species is a major 
infectious complication in the compromized host [1]. Treat­
ment of these infections with antifungal drugs generally yields 
disappointing results, especially in neutropenic patients [2]. 
Thus, there is a clear need for other forms of therapy, such as 
those enhancing natural resistance to infection.
A variety of substances, such as bacterial lipopolysaccharide 
and its derivatives, BCG, and muramyl peptides have been 
shown to increase natural resistance mechanisms [3-5]. In sys­
temic candidal infection in experimental animals, these sub­
stances were able to improve survival [6- 8], but because of 
their toxicity they have not been appealing as a therapy in 
humans. These immunomodulatory drugs are able to induce 
synthesis and secretion of interleukin 1 (IL1), a family of 
cytokines mediating the acute-phase response [9]. Previous 
investigations have shown that recombinant IL1 is able to 
increase survival in mice with a lethal infection caused by 
Pseudomonas aeruginosa and Klebsiella pneumoniae [10, 11]. 
The mechanism of this protection is unclear [11], and it is not 
known whether these findings are limited to an effect on infec­
tions due to Gram-negative bacteria. Therefore, we investi-
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gated the effect of IL 1 on an experimental candidal infection 
of mice. Efficacy of IL1 in candidal infection could not only 
offer some insight into the mechanisms of protection against 
death due to infection, but might also create new modalities 
for treatment of candidal infections in humans.
2 Materials and methods
2.1 Mice
Female 25 g Swiss Webster mice (Taconic Farms, German­
town, NY) were kept in cages (6 mice per cage) with filter lids, 
and were fed standard lab chow and water ad libitum.
2.2 IL 1
Recombinant human ILlj3 (kindly supplied by Dr. Alan 
Shaw, Biogen, Geneva) and recombinant human IL la  (kindly 
supplied by Dr. Peter Lomedico, Hoffmann-La Roche, Nut- 
ley, NJ), which contain less than 20 pg of endotoxin/mg of 
protein, were used. The IL 1 was given as a single i.p. injection 
in 2% (v/v) heat-inactivated normal mouse serum in 0.1 ml 
pyrogen-free saline. Control mice received heat-inactivated 
IL1 (100 °C for 20 min) in 2% heat-inactivated normal mouse 
serum.
2.3 Candida albicans
A strain of C. albicans, termed UC820, maintained on agar 
slants at 4°C was inoculated into 100 ml of Yeast Mould agar 
(Difco Laboratories, Detroit, MI) and cultured for 24 h at 
37 °C. After being washed twice by centrifugation at 1500 x g, 
the number of yeast cells in the suspension was counted in a
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hemocytometer, and the viability was confirmed by inoculat­
ing serial dilutions onto agar plates.
2.4 Infection model
Mice were rendered neutropenic ( < 0 .2 x l09 granulocytes/ 
liter) by means of two s.c. injections of cyclophosphamide 
(Bristol Myers, Syracuse, NY), 150 and 100 mg/kg of body 
weight, respectively, 4 days and 1 day before the i.v. injection 
of 3 x 105 C. albicans in 200 (ill phosphate-buffered saline into 
the lateral tail vein. The mice in each cage were randomized to 
receive either IL1 at different times and in different dosages, 
or heat-inactivated IL1. Survival was scored at intervals of 
6-8 h over a period of 72 h.
2.5 In vitro antifungal effects of IL 1
We examined the possibility that IL 1 might have a direct anti­
fungal effect. Using an automated spiral plater (Spiral Systems 
Inc., Cincinnati, OH) we prepared a concentration gradient of 
IL ip ranging from 0.15 to 42 ng/ml on the agar surface of 
Mueller-Hinton plates. Radial streaks of C. albicans from a 
suspension containing 1 x 105 colony forming units (cfu)/ml 
were made on the plates. After incubation overnight at 37°C 
the distance from the center to the most central point of 
growth inhibition was measured.
2.6 Quantitation of C. albicans in blood and organs
Neutropenic mice, treated either with IL1(3 or heat-inacti- 
vated IL lp 24 h earlier, received an i.v. injection of 3 x 105 
cfu of C. albicans. Blood for cultures was taken by cardiac 
puncture after C 02 asphyxia 15, 30 and 90 s and 3 and 6 min 
after the i.v. injection. In another series of experiments, mice 
were killed by C 02 asphyxia 24 h after the C. albicans injec­
tion. Immediately after death, blood cultures were taken by 
cardiac puncture, and the spleen, the left kidney and the liver 
were removed aseptically, weighed and homogenized in sterile 
saline in a tissue grinder. Blood and suspensions of tissue were 
plated on Sabouraud’s dextrose agar. After overnight incuba­
tion at 37°C, the number of cfu’s was counted.
2.7 Serum for passive transfer
Twenty-four hours after an i.p. injection of either 80 ng IL ip 
or pyrogen-free saline in 2% (v/v) normal mouse serum, mice 
were exsanguinated by cardiac puncture after C 02 asphyxia­
tion. The blood was pooled and allowed to clot, and the 
serum, separated by centrifugation, was either used immedi­
ately or stored at -70  °C.
2.8 Statistical analysis
Survival curves were analyzed using the Kaplan Meier/log rank 
test [12]. Student’s t-test was used for the results of the mi­
crobiological studies.
3 Results
3.1 Survival of mice
Recombinant human IL 1(3 was given 24 h before infection as a 
single i.p. injection in dosages of 800 ng, 80 ng or 8 ng. IL1 
induced a dose-dependent enhancement of survival in infected 
mice (Fig. la). The differences in survival between mice 
treated with IL1(3 and control animals receiving heat-inacti­
vated IL 1(3 became most prominent between 36 and 72 h after 
the injection of C. albicans. If the survival curves are consid­
ered together, the survival differences compared to control 
animals were significant for the 800 ng dose (x2 = 15.6,
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Figure 1. The effect of IL 1(3 treatment on the survival of granulocytopenic mice with a candidal infection. Recombinant human IL 1(3 was given 
as a single i.p. injection. Control mice received heat-inactivated IL 1 (100°C for 20 min). (A) The effect of different dosages of IL 1(3 given 24 h 
before infection. Each group represents 30 mice. The differences in survival compared to control animals are significant for the 800 ng dose and 
for 80 ng, but not for the 8 ng dose. (B) Survival with a single injection of 80 ng IL ip given at different times. There were 30 mice in each group. 
The controls and the group receiving 80 ng IL 1(3 24 h before infection are the same as presented in (A). The protective effect of IL lp  was similar 
whether it was given 24 h before, shortly before or 6 h after infection. (C) 80 ng IL l a  given 24 h before infection had a similar protective effect 
as 80 ng IL lp  (20 mice per group).
p <  0.001) and for 80 ng (x2 = 9.2, p<0.01), but not for the 
8 ng dose (x2 = 2.3). To investigate the efficacy of IL 1 given at 
different time points in relation to the infection, the relatively 
low dose of 80 ng (3.0 M£/kg, which equals 1.2 mg/m2) was 
used. The protective effect of this dose of IL1 was similar _  
whether it was given 24 h before, shortly before (x2 = 7.4, 53 
p <  0.01) or 6 h after infection (x2 = 5.3, p <  0.02 compared to 
controls) (Fig. lb). IL la  given at a dose of 80 ng/mouse 24 h 
before infection appeared to have the same protective effect as
80 ng IL 1(3 (Fig. lc).
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3.2 In vitro assessment of antimicrobial activity
No direct antifungal effect of IL 1 could be demonstrated when 
C. albicans were incubated in vitro with concentrations of 
IL lß up to 42 ng/ml.
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3.3 Effect of IL 1 on the number of C. albicans in vivo
The number of C. albicans in the bloodstream of neutropenic 
mice up to 6 min after i.v. injection of 3 x 105 cfu was similar 
in mice pretreated with 80 ng of IL1(3 24 h earlier and those 
that had received heat-inactivated IL1 (data not shown). We 
infer from these data that the rates of clearance of organisms 
from the bloodstream were the same in the two treatment 
groups. Using the same experimental conditions, no differ­
ences were found in the number of Candida cultured from 
blood, liver, spleen, or kidney of IL 1-treated and control ani­
mals 24 h after infection (Fig. 2). When the data were ex­
pressed as number of microorganisms per organ rather than 
per gram of tissue, the data from two groups also did not 
differ.
3.4 Passive transfer of serum
To investigate whether a humoral factor was responsible for 
the protective effect, neutropenic mice were injected i.p. with 
0.5 ml of serum obtained from mice pretreated 24 h earlier 
with either 800 ng IL 1(3 or saline containing 2% normal mouse 
serum. When the transfer was performed either at time of the
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Figure 2. Counts of colonies of C. albicans in the blood and organs of 
granulocytopenic mice 24 h after an i.v. injection of 3 x 105 cfu of C. 
albicans. Mice received either 80 ng human recombinant IL lß (light 
bars) or heat-inactivated IL lß  (dark bars) 24 h before injection. Each 
bar represents the mean ±  SD of log cfu/g tissue in 6 mice.
Figure 3. Passive transfer of serum. Serum from mice that received 
800 ng IL ip  or saline 24 h before was injected i.p. into recipient mice 
that were infected with 3 x 105 cfu of C. albicans. The mice were 
injected with the serum either shortly before the infection (■ ; n = 10) 
or 24 h after infection (A; n =  10). The survival of these mice does not 
differ from the controls (□ ; n = 20).
i.v. injection of C. albicans or 24 h later, no protection was 
obtained (Fig. 3).
4 Discussion
In these studies, we report the efficacy of a single injection of a 
low dosage of either IL 1(3 or IL la  in prolonging survival in 
neutropenic mice with disseminated C. albicans infection. 
These results extend those we have obtained for Pseudomonas 
aeruginosa in a previous study [11]. In contrast with this Gram- 
negative infection, protection against a candidal infection was 
obtained not only when IL ip was given 24 h before, but also 
when it was given simultaneously with or 6 h after the injec­
tion of C. albicans. This lack of a so-called “negative phase” 
(i.e. a period in which no protection can be induced [6]) may 
be due to the fact that the course of the candidal infection in 
these mice was somewhat more protracted than that of the 
Gram-negative bacterial infection, thus allowing more time for 
a possible beneficial effect of IL1 to be established. Alterna­
tively, there might be differences between the mechanisms of 
protection to death from bacterial and fungal infections. It is 
of interest that Kimball et al. [6] demonstrated a negative 
phase for protection by bacterial endotoxin in a C. albicans 
infection. The accelerated death rate observed in their studies 
might be due to the combined adverse effect of the infection 
and the endotoxin.
The protection against candidal infection obtained by prior 
administration of bacterial endotoxin has been attributed to 
enhancement of the clearance of C. albicans from the blood 
stream and inhibition of the outgrowth in the kidney [7]. We 
found no differences in the rate of clearance of fungi from the 
bloodstream (shortly after injection and 24 h later) and their 
outgrowth in the tissues between IL 1-treated and control ani­
mals. Since all our experiments were performed in severely 
neutropenic mice, it seems unlikely that the beneficial effect
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was mediated by neutrophils. In a previous study of lethal 
infection caused by P. aeruginosa we excluded the possibility 
that the protective effect of IL1 was directly related to the 
induction of fever, the clearance of micro-organisms from the 
bloodstream by activation of macrophages, or by a direct anti­
microbial effect [11]. A possible explanation for the beneficial 
influence of IL 1 in Gram-negative infections could be through 
a humoral mechanism, for example via acute-phase proteins, 
such as an endotoxin-binding protein [13, 14]. Because C. 
albicans does not contain endotoxin, mechanisms other than 
endotoxin-binding protein must be involved. Evidence for a 
humoral mechanism was provided by Kimball et al. who found 
that mouse serum, obtained 24 h after an endotoxin injection, 
could transfer protection against a lethal candidal infection [6]. 
Whether in their studies the protective factor was IL 1 or an 
acute-phase protein is unclear. In the present study, we were 
unable to protect mice by passive transfer of serum obtained 
24 h after an injection with 800 ng IL1. In the Pseudomonas 
infection we were also unable to transfer protection with 
serum obtained after the administration of IL 1 (unpublished 
data).
Thus, the present study indicates that the beneficial effect of 
IL 1 is not mediated through a transferable factor and cannot 
be explained by an endotoxin-antagonizing effect. It has been 
suggested that cytokines like IL 1 and tumor necrosis factor 
(TNF) contribute to death from infection [15-17]. How early 
treatment with IL1 could reduce the lethal effects of these 
cytokines is not yet known. One could speculate that this could 
be effected by occupation of cytokine receptors on cells or by 
an inhibition of endogenous cytokine production. Further 
studies are needed to elucidate these possibilities. Whichever 
the mechanism is, the protective effect could have important 
implications for the future treatment of serious candidal infec­
tions in neutropenic patients.
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